Important Information Regarding Vyzulta

Posted in Latest News on March 16, 2018.

During the March 9, 2018 Board of Optometry meeting, the board approved for addition to Rule 64B13-18.002 Formulary of Topical Ocular Pharmaceutical Agents, Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%.

Important note, Vyzulta, at this time, cannot be prescribed by certified Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on this site, and at that time Vyzulta may be prescribed by certified optometrists.

 



More Latest News

First Quarter Performance Report
November 30, 2021

Released for the
2021 – 2022 Fiscal Year Continue reading


The Annual Report and Long-Range Plan Released for Fiscal Year 2020-21
November 1, 2021

The Annual Report and Long-Range Plan for Fiscal Year 2020-21
is now online. Continue reading